Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)

Congress: ISPOR Europe 2024

Objective:

Bimekizumab is an IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, recently approved as a treatment for patients with active psoriatic arthritis (PsA) in the European Union. This study compares the cost per responder (CPR) of bimekizumab versus IL-23-targeted therapies (guselkumab and risankizumab) for the treatment of PsA patients in Spain. Based on the response rates (MDA, ACR 50 and ACR 70) published in the MAIC at week 52, CPR analyses demonstrate that it is more cost-effective to treat PsA patients in Spain with bimekizumab compared to the available therapies guselkumab and risankizumab.

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)

Recommendations for effective patient involvement in the assessment of medical devices

Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)